QCast Episode 64: Tipping Point Analysis in Clinical Trials

Tipping point analysis is used to assess how far assumptions about missing outcomes would need to change before a clinical trial conclusion changes. In this QCast episode, co-hosts Jullia and Tom discuss how tipping point analysis relates to MAR and MNAR assumptions, how it can be applied to continuous outcomes, and why identifying the tipping point is only part of the interpretation.

The practical questions start with the assumptions being tested. Trial teams need to consider whether the scenarios are clinically credible, whether treatment groups should be handled differently, and whether the method suits the endpoint. Prespecification also matters, because choices around shift values, scale, affected participants, and estimand alignment can change what the sensitivity analysis is actually assessing.

🎧 Listen to the Episode:

Key Takeaways

Why the tipping point is only part of the interpretation

A tipping point shows where a predefined study conclusion changes under alternative missing-data assumptions. Its meaning depends on whether the required shift is clinically credible and how many participants are affected. A small plausible shift may raise more concern than a larger change that would be difficult to justify clinically.

Why endpoint type changes the analysis

Continuous endpoints can often be assessed using multiple imputation and delta adjustments, but binary and time-to-event outcomes need different approaches. Binary analyses may vary response probabilities or use direct sampling, while time-to-event analyses need to account for assumptions around censoring and post-censoring outcomes.

Why prespecification and scenario choice matter

The sensitivity analysis needs to test the uncertainty that is actually relevant to the trial. The Statistical Analysis Plan (SAP) should define the analysis method, affected participants, adjustment scale, scenario range, treatment-group assumptions, and tipping point criterion. Keeping the analysis aligned with the estimand helps ensure it still addresses the intended clinical question.

Full Transcript

Jullia

Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.

Tom

I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.

Jullia

Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.

Tom

Right, so missing data is something most trial teams expect to deal with. Where does tipping point analysis fit into that picture?

Jullia

It comes in when we want to understand how much our conclusions depend on assumptions about the outcomes we haven’t observed. Tipping point analysis systematically changes those assumptions until a predefined trial conclusion changes.

That could mean a statistically significant result becomes non-significant, a confidence interval crosses a decision boundary, or an equivalence or non-inferiority conclusion is no longer supported.

Tom

So it isn’t trying to somehow reconstruct the missing values and tell us what really happened?

Jullia

No. See, we usually can’t know the true values of those missing outcomes from the observed trial data alone. But what we can do is ask how different those missing outcomes would need to be from our primary assumptions before our interpretation changes, which gives us a way of assessing the sensitivity of the result.

Tom

A lot of that comes back to MAR and MNAR. Can you give us the short version of those assumptions?

Jullia

Yes, so Missing Completely At Random, or MCAR, means the missingness is unrelated to either observed or unobserved data. Think of a sample being damaged in transport for a reason unrelated to the patient.

Missing At Random, MAR, means that after we account for the information we have observed, missingness doesn’t depend on the unobserved outcome. Many multiple-imputation approaches and mixed models rely on an MAR assumption.

Then MNAR, Missing Not At Random, is where missingness may still depend on that unobserved outcome. And the difficult part is that the observed data generally can’t tell us definitively whether MAR or MNAR is true.

Tom

Can you give me a clinical example of where that distinction could start to matter?

Jullia

So suppose patients who are doing poorly are more likely to discontinue before the final efficacy assessment. If their missing outcomes would have been worse than the values predicted under MAR, the primary analysis could give a more favourable picture than an analysis based on those alternative assumptions.

Tom

Is this something you would run whenever you have any missing data?

Jullia

Not necessarily. The decision should reflect the clinical question, the estimand, the endpoint, how much data is missing, why they’re missing, and the primary analysis. However, it becomes particularly relevant when missingness could materially affect an important conclusion.

For example, there may be imbalance in discontinuation between groups, reasons for missingness may relate to efficacy or safety, or the primary result may sit relatively close to its decision boundary.

Tom

For a continuous endpoint, what does the analysis itself actually look like?

Jullia

Well, a common starting point is multiple imputation under MAR. We generate several complete datasets by imputing the missing outcomes, analyse each dataset using the planned model, and combine the estimates to account for imputation uncertainty.

Then we introduce a delta adjustment. That’s a defined shift applied to the imputed values, not the observed ones, to represent a departure from MAR. We repeat the analysis across a range of delta values until we reach a scenario where the predefined conclusion is no longer supported.

Tom

Give me a simple example of that shift.

Jullia

Say higher values on an endpoint indicate improvement. We might start with the MAR analysis at a delta of zero, then apply increasingly negative adjustments to missing outcomes in the active-treatment group.

Perhaps the conclusion still holds at minus one and minus two, but changes at minus three. That tells us where the tipping point lies within the scenarios we evaluated.

Tom

And that feels like the point where people could misread the output. If the result tips at minus three, is minus three automatically good or bad?

Jullia

No, the number doesn’t have meaning in isolation. Its interpretation depends on the endpoint scale, observed outcomes, variability, disease severity, reasons for discontinuation, and how many participants are affected.

If the conclusion changes only when we assume that missing active-treatment outcomes are far worse than outcomes in clinically similar participants, that may provide some reassurance. If a small, plausible shift changes the conclusion, the uncertainty deserves more attention.

Tom

Does the same assumption normally get applied to both treatment groups?

Jullia

It can, but that may not reflect what happened in the trial. Participants on control might discontinue because of limited efficacy, while participants on active treatment might discontinue because of adverse events.

So the analysis can use treatment-specific assumptions. You can also vary assumptions in both groups simultaneously and display the combinations where the conclusion is retained or lost.

Tom

We’ve been talking mainly about continuous outcomes. What changes when the endpoint is binary?

Jullia

Well, with a binary endpoint, you’re dealing with categories such as responder and non-responder, so you can’t simply add a numerical delta to an observed binary value. Instead, you can vary assumptions about response among participants with missing outcomes. That might involve changing response probabilities by treatment group or directly sampling missing binary outcomes from assumed probabilities.

There’s also an important scale issue. A shift on the log-odds scale doesn’t necessarily translate into a fixed change in response probability, so the method has to match the question you actually want the sensitivity analysis to test.

Tom

And time-to-event endpoints bring censoring into it rather than a straightforward missing final value?

Jullia

Exactly, see, with outcomes such as overall survival or progression-free survival, the uncertainty may be around what happens after censoring. Sensitivity analyses can examine departures from assumptions about independent or non-informative censoring, for example by varying post-censoring hazards or imputing alternative event times. There isn’t one tipping point method that fits every survival analysis. It has to reflect the endpoint, censoring process, estimand, and primary model.

Tom

Once you start building these analyses, where are the easiest places to get them wrong?

Jullia

One is choosing a delta range that doesn’t really challenge the primary assumption, or going so wide that the scenarios stop being clinically useful. And scale matters as well. A delta on the original endpoint scale can mean something quite different from a shift on a transformed or model-link scale.

And you also need to be clear about which participants are being adjusted and why. Missingness after an administrative disruption may warrant different assumptions from missingness after lack of efficacy or an adverse event.

Tom

There’s a temptation there to run enough scenarios until you find one that supports the result you want. How do you avoid that?

Jullia

Prespecification helps. The Statistical Analysis Plan should describe the method, who is affected, the adjustment scale, treatment-group assumptions, scenario range, increments, pooling method, and the criterion used to define the tipping point.

You also need to keep the sensitivity analysis aligned with the estimand. If you change the population, endpoint definition, or handling of intercurrent events, you may end up answering a different clinical question rather than testing the assumptions behind the original one.

Tom

If you evaluate a wide range of scenarios and never find a tipping point, can you say the study result is proven to be insensitive to missing data?

Jullia

Only within the range you actually tested. No tipping point means the conclusion remained consistent across those evaluated assumptions. It doesn’t prove the conclusion would survive every possible MNAR scenario.

And tipping point analysis can’t tell us the true missing outcomes, prove that MAR is correct, or tell us how likely a particular scenario is. After all, it’s a sensitivity assessment, and not a way of removing the uncertainty created by missing data.

Tom

If someone listening is planning one of these analyses now, what are the few things you’d want them to keep in mind?

Jullia

First, define clearly which conclusion you’re stress-testing and keep the sensitivity analysis aligned with the estimand. Second, make sure the assumptions and shifts have a clinical interpretation rather than treating the tipping point as a purely numerical result.

And finally, match the method to the endpoint. Continuous, binary, and time-to-event outcomes raise different analytical questions, even though the overall aim is the same. This being understanding how dependent the study conclusion is on assumptions we can’t verify directly. So the value really comes from knowing what was tested and what would change the interpretation.

With that, we’ve come to the end of today’s episode on tipping point analysis in clinical trials. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.

Tom

Thanks for tuning in, and we’ll see you in the next episode.

About QCast

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.